RxDoctor Payments Data

Carl Earnest, MD

Internal Medicine · Longview, TXNPI 1699832873

Payments from drug & device makers

$2,598in general payments, 2019–2025

Across 174 payments — averaging $14.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$559
  • Novo Nordisk$353
  • Pfizer$315
  • AstraZeneca$311
  • Johnson & Johnson$222
  • Sanofi-aventis U.S. LLC$187
  • plus $651 from 10 others

What the payments were for

  • Food & beverage$2,57799%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,598 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$220,672
Medicare patients
804
Services billed
2,663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban588$270,755
TrulicityDulaglutide211$210,594
XareltoRivaroxaban208$120,596
Kesimpta PenOfatumumab12$110,748
OzempicSemaglutide92$104,065
FarxigaDapagliflozin Propanediol135$70,108
JanuviaSitagliptin Phosphate95$61,143
MyrbetriqMirabegron100$45,474
MounjaroTirzepatide41$42,667
CompleraEmtricita/Rilpivirine/Tenof Df11$42,518
JardianceEmpagliflozin64$42,490
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog128$40,135
DovatoDolutegravir Sodium/Lamivudine12$36,426
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$33,498
Tresiba Flextouch U-100Insulin Degludec51$26,428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$315$270,755588 claims
Lilly USA, LLCTrulicity, Mounjaro$119$253,261252 claims
Johnson & JohnsonXarelto, Complera, Invokana$222$175,780245 claims
Novo NordiskOzempic, Rybelsus, Fiasp$353$127,770132 claims
AstraZenecaFarxiga, Symbicort$311$80,262176 claims
MerckJanuvia, Janumet Xr$115$72,721108 claims
Boehringer IngelheimJardiance, Spiriva Respimat$85$53,21284 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy$27$49,25997 claims
NovartisEntresto$28$20,83053 claims
AbbVieLinzess$59$12,86217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →